ACS B.V. establishes two new autonomous subsidiaries, launches a new global brand and appoints an exclusive distributor in the Netherlands.
Venlo, The Netherlands, June 10, 2013 - ACS B.V. the Dutch innovative developer of outperforming thermoelectrics. for the Photonics market, today announces the establishment of two separate subsidiaries to each address the world-wide Health- and Industrial markets respectively.
Under the umbrella of the registered brand "Qill® ", ACS will offer highly effective new cold-warm therapies delivered by means of innovative outperforming products that stand for Quality in living your life.
Qill® HEALTH B.V.
will develop, manufacture and market innovative healthcare products including therapies for a faster- and less painful recovery of sports- and other non-invasively treated injuries. The patent-pending product that will be launched in Q2 2013 will boost the effectiveness of thermal contrast treatments as widely used by physiotherapists today.
Qill® is a registered trademark owned by ACS B.V. and brings innovative quality branded products and applications to the health- and industrial markets utilizing an outperforming thermoelectric technology for heating- and cooling liquids. (www.qill.eu)
You can buy our products via dedicated distributors.